RBT-1
Phase 3Small molecule
RBT-1 is one of 33 small molecule programs targeting Complication. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Aranesp
AmgenPreclinical
RBT-1
RRenibus Therapeutics, Inc.
Phase 3
Uloric
TakedaPreclinical
Lorelco
SanofiPreclinical
Sovaldi
GileadPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Genotropin
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Kidney Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RBT-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRenibus Therapeutics, Inc.